ALERTS & COVID-19 UPDATES Learn more: COVID-19 Resources; COVID-19 Testing; Vaccine Info; Visitor Policy; Support Us

[LCID Study Number: 2016-072]

Simplifying and Protocolizing Intrapleural Lytic Instillation Therapy (SPLIT Trial)

The primary objective of this study is to evaluate improvement in area of pleural opacity on chest radiographs comparing Day 1 to Day 7 in patients with empyema and parapneumonic effusions. The standard approach for treating patients with empyema and parapneumonic effusions is fixed dosing of tPA and DNase twice a day for a total of 6 doses (3 days). If the patient is randomized to arm 2 (variable dosing), his or her fluid output and chest x-ray will be closely monitor. Whether the dose will be continued or stopped will depend of the fluid output and improvement of effusion area on x-ray. If the fluid output <200 mL and there is a ≥ 30% improvement of effusion area on 2-view x-ray, then the dose will be stopped. The total dose will not exceed 6 doses.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3240